1
|
Aussedat P, Chebib N, Ahmad K, Glerant J, Maury J, Nasser M, Thivolet-Bejui F, Traclet J, Turquier S, Chalabreysse L, Tronc F, Cottin V. Impact de la biopsie pulmonaire chirurgicale sur la fonction respiratoire dans la fibrose pulmonaire idiopathique. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
4
|
Chebib N, Turquier S, Khouatra C, Philit F, Traclet J, Sénéchal A, Zeghmar S, Mornex J, Cottin V. Hypertension pulmonaire au cours des pneumopathies interstitielles diffuses idiopathiques. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Chebib N, Turquier S, Khouatra C, Philit F, Traclet J, Sénéchal A, Zeghmar S, Mornex JF, Cottin V. Hypertension pulmonaire associée aux maladies respiratoires chroniques : comparaison avec l’hypertension artérielle pulmonaire. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Chebib N, Khouatra C, Lazor R, Archer F, Leroux C, Gamondes D, Thivolet-Bejui F, Cordier JF, Cottin V. [Pulmonary lymphangioleiomyomatosis: From pathogenesis to management]. Rev Mal Respir 2015; 33:718-734. [PMID: 26604019 DOI: 10.1016/j.rmr.2015.10.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Accepted: 10/06/2015] [Indexed: 12/24/2022]
Abstract
INTRODUCTION Pulmonary lymphangioleiomyomatosis (LAM) is a rare disease affecting mainly young women. BACKGROUND The respiratory manifestations are characterized by a progressive cystic destruction of the lung parenchyma. Extrapulmonary involvement includes benign renal tumours called angiomyolipomas and abdominal lymphatic masses called lymphangioleiomyomas. At the pathological level, the cellular proliferation found in LAM is in part due to the presence of mutations in the tumour suppressor genes TSC1 and TSC2 (Tuberous Sclerosis Complex). These mutations lead to the activation of the mTOR pathway, which is currently the main therapeutic target. mTOR inhibitors such as sirolimus or everolimus have shown a beneficial effect on the decline in pulmonary function and a reduction of angiomyolipoma size, but are necessary in only some patients. PERSPECTIVES LAM cells have migratory properties mediated by the formation of new lymphatic vessels. They are also able to secrete metalloproteases, which enhance their invasiveness. Moreover, the expression of estrogen and progesterone receptors by LAM cells suggests a possible role for sex hormones in the pathogenesis of the disease. CONCLUSION A better understanding of mTOR-independent mechanisms would allow the development of novel therapeutic approaches.
Collapse
Affiliation(s)
- N Chebib
- Service de pneumologie, centre de référence des maladies pulmonaires rares, hôpital Louis-Pradel, hospices civils de Lyon, 8, avenue du Doyen-Lépine, 69677 Lyon cedex, France; UMR 754 Inra, université de Lyon, université Claude-Bernard Lyon 1, 69366 Lyon cedex, France
| | - C Khouatra
- Service de pneumologie, centre de référence des maladies pulmonaires rares, hôpital Louis-Pradel, hospices civils de Lyon, 8, avenue du Doyen-Lépine, 69677 Lyon cedex, France
| | - R Lazor
- Service de pneumologie, centre de référence des maladies pulmonaires rares, hôpital Louis-Pradel, hospices civils de Lyon, 8, avenue du Doyen-Lépine, 69677 Lyon cedex, France; Unité des pneumopathies interstitielles et maladies pulmonaires rares, service de pneumologie, centre hospitalier universitaire vaudois, 1011 Lausanne, Suisse
| | - F Archer
- UMR 754 Inra, université de Lyon, université Claude-Bernard Lyon 1, 69366 Lyon cedex, France
| | - C Leroux
- UMR 754 Inra, université de Lyon, université Claude-Bernard Lyon 1, 69366 Lyon cedex, France
| | - D Gamondes
- Service de radiologie, hôpital Louis-Pradel, hospices civils de Lyon, 69677 Lyon cedex, France
| | - F Thivolet-Bejui
- Centre de pathologie Est, groupement hospitalier Est, hospices civils de Lyon, 69677 Lyon cedex, France
| | - J F Cordier
- Service de pneumologie, centre de référence des maladies pulmonaires rares, hôpital Louis-Pradel, hospices civils de Lyon, 8, avenue du Doyen-Lépine, 69677 Lyon cedex, France; UMR 754 Inra, université de Lyon, université Claude-Bernard Lyon 1, 69366 Lyon cedex, France
| | - V Cottin
- Service de pneumologie, centre de référence des maladies pulmonaires rares, hôpital Louis-Pradel, hospices civils de Lyon, 8, avenue du Doyen-Lépine, 69677 Lyon cedex, France; UMR 754 Inra, université de Lyon, université Claude-Bernard Lyon 1, 69366 Lyon cedex, France.
| |
Collapse
|
8
|
Valour F, Chebib N, Gillet Y, Reix P, Laurent F, Chidiac C, Ferry T. [Staphylococcus aureus broncho-pulmonary infections]. Rev Pneumol Clin 2013; 69:368-382. [PMID: 24183294 DOI: 10.1016/j.pneumo.2013.08.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2013] [Revised: 07/30/2013] [Accepted: 08/05/2013] [Indexed: 06/02/2023]
Abstract
Staphylococcus aureus accounts for 2-5% of the etiologies of community-acquired pneumonia. These infections occur mainly in elderly patients with comorbidity, after a respiratory viral infection. S. aureus could also be responsible for necrotizing pneumonia, which occurs in young subjects, also after flu. Necrotizing pneumonia are associated with the production of a particular staphylococcal toxin called Panton-Valentine leukocidin, responsible for pulmonary focal necrosis, occurrence haemoptysis, leucopenia, and death. In Europe, these strains are still predominantly sensitive to anti-staphylococcal penicillin, which must be used at high dosage intravenously in combination with an antibiotic that reduces toxin production such as clindamycin, and intravenous immunoglobulin in severe cases. The mortality rate is estimated at 50%. In addition, S. aureus is one of the pathogens involved in early respiratory infections in cystic fibrosis patients, in whom methicillin resistance plays an important prognostic role. However, the involvement of S. aureus in COPD exacerbations is rare. Finally, S. aureus represents 20 to 30% of cases of hospital-acquired pneumonia, including ventilator-associated pneumonia. In these cases, methicillin-resistance is common and requires the use of glycopeptides or linezolid. The place of new anti-staphylococcal antibiotics such as new generation cephalosporins or tigecyclin remains to be defined.
Collapse
Affiliation(s)
- F Valour
- Service des maladies infectieuses et tropicales, hospices civils de Lyon, hôpital de la Croix-Rousse, groupement hospitalier Nord, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France; Université Claude-Bernard Lyon 1, 69008 Lyon, France; Inserm U1111, CNRS UMR5308, ENS de lyon, UCBL1, Centre international de recherche en infectiologie (CIRI), 69007 Lyon, France; Centre national de référence des staphylocoques, hospices civils de Lyon, 69008 Lyon, France
| | - N Chebib
- Service des maladies infectieuses et tropicales, hospices civils de Lyon, hôpital de la Croix-Rousse, groupement hospitalier Nord, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France
| | - Y Gillet
- Université Claude-Bernard Lyon 1, 69008 Lyon, France; Inserm U1111, CNRS UMR5308, ENS de lyon, UCBL1, Centre international de recherche en infectiologie (CIRI), 69007 Lyon, France; Centre national de référence des staphylocoques, hospices civils de Lyon, 69008 Lyon, France; Service d'urgences pédiatriques, hospices civils de Lyon, hôpital Femme-Mère-Enfant, 69500 Bron, France
| | - P Reix
- Université Claude-Bernard Lyon 1, 69008 Lyon, France; Service de pneumologie, allergologie, mucoviscidose, hospices civils de Lyon, hôpital Femme-Mère-Enfant, 69500 Bron, France
| | - F Laurent
- Université Claude-Bernard Lyon 1, 69008 Lyon, France; Inserm U1111, CNRS UMR5308, ENS de lyon, UCBL1, Centre international de recherche en infectiologie (CIRI), 69007 Lyon, France; Centre national de référence des staphylocoques, hospices civils de Lyon, 69008 Lyon, France; Laboratoire de bactériologie, hospices civils de Lyon, groupement hospitalier Nord, 69004 Lyon, France
| | - C Chidiac
- Service des maladies infectieuses et tropicales, hospices civils de Lyon, hôpital de la Croix-Rousse, groupement hospitalier Nord, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France; Université Claude-Bernard Lyon 1, 69008 Lyon, France; Inserm U1111, CNRS UMR5308, ENS de lyon, UCBL1, Centre international de recherche en infectiologie (CIRI), 69007 Lyon, France; Centre national de référence des staphylocoques, hospices civils de Lyon, 69008 Lyon, France
| | - T Ferry
- Service des maladies infectieuses et tropicales, hospices civils de Lyon, hôpital de la Croix-Rousse, groupement hospitalier Nord, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France; Université Claude-Bernard Lyon 1, 69008 Lyon, France; Inserm U1111, CNRS UMR5308, ENS de lyon, UCBL1, Centre international de recherche en infectiologie (CIRI), 69007 Lyon, France; Centre national de référence des staphylocoques, hospices civils de Lyon, 69008 Lyon, France.
| |
Collapse
|